BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research

BioStem remains committed to advancing evidence-based innovation in wound care through rigorous clinical research and real-world data analysis, supported by its proprietary BioRetain ® process and ...
JD Supra

FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials

In a new draft guidance issued on January 14, 2026, the FDA discussed the use of a modern statistical methodology in clinical trials designed to ...
The BMJ

FDA is now “open to bayesian statistics”: transformational change or new Pandora’s box?

The US Food and Drug Administration (FDA) is now “open to bayesian statistics,” contrasting this with the frequentist approach that the agency and the drug industry have historically relied on for ...
JSTOR Daily

Bayesian Analysis of Proportional Hazards Models Built from Monotone Functions

We consider the usual proportional hazards model in the case where the baseline hazard, the covariate link, and the covariate coefficients are all unknown. Both the baseline hazard and the covariate ...
JSTOR Daily

Multivariate Fay–Herriot Bayesian estimation of small area means under functional measurement error

Journal of the Royal Statistical Society. Series A (Statistics in Society), Vol. 180, No. 4 (OCTOBER 2017), pp. 1191-1209 (19 pages) Area level models, such as the Fay–Herriot model, aim to improve ...